Abstract
Background: Chlamydia trachomatis(CT) and Neisseria gonorrhoeae (NG) are the most common bacterial sexually transmitted infections (STIs) worldwide. In the absence of affordable point-of-care STI tests, WHO recommends STI testing based on risk factors. This study aimed to develop a prediction tool with a sensitivity of >90% and efficiency (defined as the percentage of individuals that are eligible for diagnostic testing) of <60%. Methods: This study offered CT/NG testing as part of a cluster-randomised trial of community-based delivery of sexual and reproductive health services to youth aged 16-24 years in Zimbabwe. All individuals accepting STI testing completed an STI risk factor questionnaire. The outcome was positivity for either CT or NG. Backwards-stepwise logistic regression was performed with p≥0.05 as criteria for exclusion. Coefficients of variables included in the final multivariable model were multiplied by 10 to generate weights for a STI risk prediction tool. A maximum likelihood Receiver Operating Characteristics (ROC) model was fitted, with the continuous variable score divided into 15 categories of equal size. Sensitivity, efficiency and number needed to screen were calculated for different cut-points. Findings: From 3 December 2019 to 5 February 2020, 1007 individuals opted for STI testing, of whom 1003 (99.6%) completed the questionnaire. CT/NG prevalence was 17.5% (95%CI 15.1, 19.8) (n=175). CT/NG positivity was independently associated with being female, number of lifetime sexual partners, relationship status, HIV status, self-assessed STI risk and past or current pregnancy. The STI risk prediction score including those variables ranged from 2 to 46 with an area under the ROC curve of 0.72 (95%CI 0.68, 0.76). Two cut-points were chosen: i) 23 for optimised sensitivity (75.9%) and specificity (59.3%) and ii) 19 to maximise sensitivity (82.4%) while keeping efficiency at <60% (59.4%). Interpretation: The high prevalence of STIs among youth, even in those with no or one reported risk factor, may preclude the use of risk prediction tools for selective STI testing. At a cut-point of 19 one in six young people with STIs would be missed. Trial Registration: This study was nested within a cluster-randomised trial (CHIEDZA) of an integrated package of HIV and sexual and reproductive health (SRH) services for youth delivered in community-based settings in Zimbabwe (registered in clinical trials.gov: NCT03719521) Funding Statement: The study is funded by the Wellcome Trust. Declaration of Interests: The authors declare no conflict of interest. Ethics Approval Statement: Written informed consent was obtained from study participants. This study was approved by the LSHTM Research Ethics Committee (16948) and the Medical Research Council of Zimbabwe (MRCZ/A/2387).
Highlights
Chlamydia trachomatis and Neisseria gonorrhoeae are the most common bacterial sexually transmitted infections (STIs) worldwide
An individual participant data meta-analysis including women participating in 18 HIV prevention studies in sub-Saharan Africa recruited mostly before 2010 showed that chlamydia and gonorrhoea prevalence was generally higher among the 15-24 year olds compared to the 25–49 year olds [15]
Between 3 December 2019 and 5 February 2020; 1007 individuals opted for STI testing of whom 1003 gave consent for data on risk factors to be collected
Summary
Chlamydia trachomatis and Neisseria gonorrhoeae are the most common bacterial sexually transmitted infections (STIs) worldwide These conditions have important sexual, reproductive, and maternal-child health consequences, including genital symptoms, pregnancy complications, infertility, enhanced HIV transmission, and psychological effects [1,2,3,4,5,6,7,8]. An individual participant data meta-analysis including women participating in 18 HIV prevention studies in sub-Saharan Africa recruited mostly before 2010 showed that chlamydia and gonorrhoea prevalence was generally higher among the 15-24 year olds compared to the 25–49 year olds [15]. This study aimed to develop a prediction tool with a sensitivity of > 90% and efficiency (defined as the percentage of individuals that are eligible for diagnostic testing) of < 60%
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.